SensiScreen Liquid
The EpiDirect® MGMT Methylation qPCR Assay represents a new and innovative approach allowing for direct evaluation of MGMT promoter methylation by qPCR without prior DNA conversion.
The EpiDirect® technology is based on our unique INA® chemistry and includes an EpiPrimer™ oligonucleotide that specifically binds and primes amplification of methylated target DNA.
- No need for prior conversion of DNA
- Results in less than 2 hours
- One instrument procedure
- Minimal hands-on time
- 1.5-3% LoD
klkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkk
cfdddddddddddddddddddddddd dddddddddddddddddddddddd ddd
Product information
Specimens: Formalin-fixed paraffin-embedded (FFPE) glioblastoma biopsies
Minimum tumor cell percentage: 20%
Input:
Validated real-time PCR instruments: QuantStudio™ 5 (Applied Biosystems), CFX Opus 96 (Bio-Rad), BaseTyper
Downloads
Publications
A qPCR technology for direct quantification of methylation in untreated DNA. Bendixen KK, Mindegaard M, Epistolio S, Dazio G, Marchi F, Spina P, Arnspang EC, Soerensen M, Christensen UB, Frattini M, Petersen RK. Nature Communications 2023 24;14(1):5153. https://doi.org/10.1038/s41467-023-40873-y
